Shares of Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) shot up 24.1% during mid-day trading on Wednesday . The company traded as high as C$1.72 and last traded at C$1.70. 892,106 shares were traded during mid-day trading, an increase of 556% from the average session volume of 135,968 shares. The stock had previously closed at C$1.37.
Analyst Ratings Changes
Separately, Jones Trading cut shares of Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 16th.
View Our Latest Stock Analysis on ONC
Oncolytics Biotech Stock Down 6.2%
The firm has a market cap of C$116.38 million, a price-to-earnings ratio of -4.21 and a beta of 1.35. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. The business's 50-day moving average is C$0.79 and its 200-day moving average is C$0.94.
About Oncolytics Biotech
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Read More
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
